BioHarvest Sciences (NASDAQ:BHST – Get Free Report) is expected to release its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect BioHarvest Sciences to post earnings of ($0.16) per share and revenue of $9.31 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.
BioHarvest Sciences (NASDAQ:BHST – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.04). The company had revenue of $8.84 million during the quarter, compared to analysts’ expectations of $9.45 million. BioHarvest Sciences had a negative net margin of 31.21% and a negative return on equity of 58.30%. On average, analysts expect BioHarvest Sciences to post ($0.58) EPS for the current fiscal year and ($0.42) EPS for the next fiscal year.
BioHarvest Sciences Stock Down 5.2%
Shares of NASDAQ:BHST opened at $1.46 on Thursday. BioHarvest Sciences has a 52-week low of $1.37 and a 52-week high of $9.25. The stock has a market cap of $28.65 million, a P/E ratio of -2.81 and a beta of 0.93. The business has a fifty day moving average of $1.67 and a two-hundred day moving average of $3.20.
Analyst Ratings Changes
Several brokerages have recently weighed in on BHST. Roth Capital lowered their price target on shares of BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Monday, September 14th. Finally, Maxim Group cut their price objective on shares of BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $6.50.
View Our Latest Report on BHST
BioHarvest Sciences Company Profile
BioHarvest Sciences Inc is a biotechnology company developing health and wellness products through its proprietary Botanical Synthesis technology. The platform is designed to produce plant-based compounds in controlled environments without relying on conventional agricultural cultivation of the whole plant, with the goal of preserving targeted botanical molecules and improving production consistency.
The company’s primary commercial product is VINIA, a dietary supplement made from a proprietary red grape cell culture and marketed for its polyphenol content and potential cardiovascular and general wellness benefits.
Read More
- Five stocks we like better than BioHarvest Sciences
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
